Okidol (Ketoprofen Lysine)

Ketoprofen lysine, the active ingredient in Okidol, is a non-steroidal anti-inflammatory drug (NSAID) presented as a 50 mg tablet for oral use. It is employed to relieve pain and inflammation in musculoskeletal conditions and is commonly prescribed for adults.

GNH USA supplies Okidol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Okidol is an NSAID that acts on inflammatory pathways to reduce pain and swelling. - Rheumatoid arthritis: helps decrease joint pain and swelling, improving mobility. - Osteoarthritis: provides analgesic relief for chronic joint degeneration. - Acute musculoskeletal injury: alleviates pain and inflammation following sprains, strains or bruises.

Ketoprofen lysine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dyspepsia or stomach upset - Headache - Dizziness - Nausea - Mild skin rash - Elevated liver enzymes

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulceration - Severe skin reactions such as Stevens‑Johnson syndrome - Renal impairment or failure - Hepatotoxicity - Anaphylaxis or severe allergic reaction - Cardiovascular events such as myocardial infarction

When using Okidol, consider the following safety measures: - Assess renal function: patients with impaired kidney function require monitoring. - Evaluate hepatic status: liver disease may increase risk of toxicity. - Review cardiovascular risk: NSAIDs can affect blood pressure and clotting. - Avoid concurrent use with other NSAIDs or anticoagulants unless medically justified. - Use gastro‑protective agents if long‑term therapy is anticipated. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Ketoproline lysine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin) – increased bleeding risk. - Selective COX‑2 inhibitors (e.g., celecoxib) – additive gastrointestinal toxicity.\nModerate Interactions (Monitor Closely): - ACE inhibitors or ARBs – may reduce renal perfusion. - Diuretics – heightened risk of kidney injury. - Lithium – NSAIDs can raise lithium serum levels. - Methotrexate – reduced clearance may increase toxicity.